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Morpholinorotein-tyrosine phosphatase (PTP) that is expressed in vascular endothelial cells
and has tumor suppressor activity. Mouse models with gene targeted Dep1 either show vascular defects, or
do not show any defects at all. We used the zebraﬁsh to investigate the role of Dep1 in early development.
The zebraﬁsh genome encodes two highly homologous Dep1 genes, Dep1a and Dep1b. Morpholinos speciﬁc
for Dep1a and Dep1b induced defects in vasculature, resulting in defective blood circulation. However, Green
Fluorescent Protein expression in ﬂi1a::gfp1 transgenic embryos and cdh5 expression, markers of vascular
endothelial cells, were normal upon Dep1a- and Dep1b-MO injection. Molecular markers indicated that
arterial speciﬁcation was reduced and venous markers were expanded in Dep1 morphants. Moreover, the
Dep1a/Dep1b knockdowns were rescued by inhibition of Phosphatidylinositol-3 kinase (PI3K) and by
expression of active Notch and Grl/Hey2. Our results suggest a model in which Dep1 acts upstream in a
signaling pathway inhibiting PI3K, resulting in expression of Notch and Grl, thus regulating arterial
speciﬁcation in development.
© 2008 Elsevier Inc. All rights reserved.IntroductionProtein phosphorylation on tyrosine residues is an important cell
signaling mechanism that controls fundamental cellular processes,
including proliferation, differentiation and migration. The phospho-
rylation state is governed by the opposing activities of protein-
tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs)
(Hunter, 1995). Like the PTKs, the PTPs represent a large family of
enzymes with cytoplasmic and transmembrane members. Still
relatively little is known about the function of PTPs in development.
The classical PTPs are subdivided into 17 subfamilies based on the
alignment of the highly conserved catalytic PTP domain. The trans-
membrane PTPs are tentatively called receptor PTPs (RPTPs) because of
their potential to signal across the membrane. Most RPTPs encode two
cytoplasmic PTP domains. However, the R3 Receptor Protein-Tyrosine
Phosphatase (RPTP) subfamily, comprising Dep1 (also known as CD148
andRPTPeta), SAP-1, PTPβ andGlepp1 encode a single PTP domain (den
Hertog,1999; Alonso et al., 2004; Andersen et al., 2004). Dep1 has eight
Fibronectin type III (FNIII) motifs in its extracellular region. Dep1
expression was enhanced 10-fold in WI-38 human embryonic lung
ﬁbroblasts growing in monolayer when they approached conﬂuence,
hence the name density-enhanced PTP1, Dep1 (Ostman et al., 1994).
Dep1 is expressed in vascular endothelial cells of the arterial and
capillary vessels of a number of organs (Borges et al., 1996; Takahashi
et al., 1999, 2003). In addition, Dep1 is expressed in differentrtog).
l rights reserved.hematopoietic derived cell lineages (de la Fuente-Garcia et al., 1998).
Dep1 shows tumor suppressor activity when overexpressed in
cultured tumor cells (Keane et al., 1996; Trapasso et al., 2000). The
mouse Ptprj gene, encoding Dep1, is a candidate for the colon-cancer
susceptibility locus Scc1. Moreover, the human PTPRJ gene is
frequently deleted in human cancers (Ruivenkamp et al., 2002).
Taken together, Dep1 is an important tumor suppressor gene.
Gene targeting of Dep1 in the mouse by in-frame replacement of
cytoplasmic sequences with enhanced Green Fluorescent Protein
(GFP) sequences resulted in embryos that died at midgestation, before
embryonic day 11.5 with vascularization failure and disorganized
vascular structures. Homozygous mutant embryos displayed subtle
defects, such as enlarged vessels comprised of endothelial cells as early
as embryonic day 8.25. These Dep1 mutant mice implicated a role for
Dep1 in endothelial proliferation and in vascular organization during
development (Takahashi et al., 2003). However, the molecular
mechanisms underlying the phenotype are still unclear. Surprisingly,
genetic ablation of Dep1 by deletion of exons 3, 4 and 5 by homologous
recombination, did not affect mouse development. In fact, homo-
zygous Ptprj−/−mice are viable and fertile. Immunoblotting conﬁrmed
that these mice do not express Dep1 protein (Trapasso et al., 2006).
Recent work in C. elegans indicated a role for Dep1 in binary cell fate
decisions. Dep1 acts as a negative regulator of EGFR signaling and
through an intricate feedback mechanism, Dep1 ampliﬁes the small
difference in EGFR signaling, resulting in full activation of the EGFR/
RAS/MAPK pathway in primary vulval cells and inactivation of this
pathway in secondary cells (Berset et al., 2005), thus effectively
determining cell fate in vulval development.
Fig. 1. Dep1a and Dep1b are orthologs of human Dep1 and are broadly expressed during
early development. (A) Phylogenetic tree of Dep1 and its most closely related family
members, PTPβ and SAP1. The PTP domains of zebraﬁsh (D. rerio), human (H. sapiens)
and mouse (M. mus) R3 subfamily members were plotted, based on sequence identity.
(B) Genomic localization of human Dep1 (Chr. 11), Dep1a (LG7) and Dep1b (LG25) and
genes in their immediate surroundings. (C–L) Dep1a- and dep1b-speciﬁc riboprobes,
encompassing the catalytic domain, were generated and used in whole-mount in situ
hybridization. Whole-mount expression of dep1a (C–E) and dep1b (F–H) during early
zebraﬁsh development, 4 cell stage (C,F), 4 hpf (D,G) and 30 hpf (E,H) are depicted as
well as sections of 30 hpf and 48 hpf embryos (I–L). Relevant structures were labeled:
DA, dorsal aorta; NC, notochord, NT, neural tube; PCV, posterior cardinal vein.
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vertebrate development. The zebraﬁsh genome encodes two Dep1
proteins, Dep1a and Dep1b. Morpholino-injections targeting Dep1a,
Dep1b, or both, indicated that the two Dep1s were essential for
normal blood circulation. Dep1 knockdown resulted in reduced
arterial markers and expanded venous markers. Rescue experiments
indicated that Phosphatidylinositol-3-Kinase (PI-3 Kinase), Grl/hey2
and Notch signaling were involved in Dep1 function. Our results
indicate that Dep1 is required for the arterial–venous cell fate
decision.
Results
Zebraﬁsh dep1a and dep1b are ubiquitously expressed
The zebraﬁsh genome encodes two dep1 genes, dep1a (Zv6,
ENSDARG00000011567) and dep1b (Zv6, ENSDARG00000033042).
Zebraﬁsh Dep1a comprises 12 Fibronectin type III like repeats, four
more than mammalian Dep1. The 5′ sequence of dep1b is not
complete and therefore the number of Fibronectin type III like repeats
in Dep1b remains to be determined. Sequence alignments of the PTP
domain of Dep1a and Dep1b show highest homology to human Dep1
(data not shown). The catalytic domains of Dep1a and Dep1b have 68%
and 65% sequence identity with human Dep1, respectively. We have
identiﬁed other R3 subfamily members in zebraﬁsh, including PTPβ
(Zv6, ENSDARG00000006391) and SAP-1 (Zv6, ENSDARG
00000063620). A phylogenetic tree illustrates that indeed Dep1a
and Dep1b resemble mammalian Dep1s more than the other R3
subfamily members, PTPβ and SAP-1 (Fig. 1A). Moreover, comparison
of synteny between the zebraﬁsh dep1s and human PTPRJ, encoding
Dep1, indicated that both dep1 genes have the same ﬂanking genes as
human PTPRJ and thus that dep1a and dep1b indeed are orthologs of
human PTPRJ (Fig. 1B).
We obtained the full length dep1a cDNA by RT-PCR from 3 dpf
zebraﬁsh embryos. Five overlapping fragments were obtained by PCR,
based on the ENSEMBL prediction of the gene. We assembled these
fragments and generated the full length 4953 bp coding sequence of
dep1a. In addition, we obtained a fragment of dep1b by RT-PCR,
encoding the catalytic PTP domain.
We used fragments of dep1a and dep1b, encompassing the catalytic
PTP domains as probes for in situ hybridization to establish the
expression patterns of dep1a and dep1b. We found that both genes
were maternally expressed (4 cell stage) and displayed ubiquitous
expression at early stages of development, 4 hpf and 30 hpf (Figs. 1C–
H). Sections of 30 hpf and 48 hpf embryos demonstrated that dep1a
and dep1b are widely expressed in muscles, the neural tube and
vascular endothelial cells (Figs. 1I–L). Several other dep1a-speciﬁc
probes were generated using more 5′ sequences and in situ
hybridizations using these probes resulted in similar expression
patterns as with the dep1a PTP domain probe (data not shown). Since
we detected expression of dep1b, we conclude that this is a bona ﬁde
gene and not a pseudogene. Control sense riboprobes for dep1a and
dep1b did not result in speciﬁc staining (data not shown). Taken
together, our results demonstrate that the zebraﬁsh genome encodes
two dep1 genes that are both expressed ubiquitously during early
zebraﬁsh development.
Dep1a-MO induced blood circulation defects
To study the function of Dep1a during zebraﬁsh development, we
targeted Dep1a expression using speciﬁc morpholinos (MOs). We
designed two splice site MOs, directed at exon 21 and exon 22, well
upstream of the catalytic site cysteine, Dep1a-MO1 and Dep1a-MO2,
respectively (Fig. 2A). We tested the efﬁcacy of these MOs by RT-PCR
using exon-speciﬁc primers on total RNA from non-injected control
embryos and embryos injected with Dep1a-MO1 or Dep1a-MO2. Both
Fig. 2. Dep1a- and Dep1b-MOs efﬁciently blocked splicing. (A) Dep1a-MO1 and Dep1a-MO2 target the 3′ end of exon 21 and exon 22, respectively. Exon-speciﬁc primers were
designed in exon 21 and exon 23, allowing PCR of spliced RNA (287 bp) and improperly spliced mRNA (333 bp and 313 bp), respectively. RT-PCR was done on non-injected control
(WT), Dep1a-MO1 and Dep1a-MO2-injected embryos. The sizes of the obtained PCR fragments on an agarose gel are indicated. (B) The Dep1b-MO targets the 3′ end of exon 25, which
encodes sequences corresponding to exon 21 of dep1a (see also Supplementary Fig. S1). Oligos were designed against exon 25 and intron 25, allowing PCR of unspliced dep1b RNA
(370 bp) and as a control, exon-speciﬁc primers were used (672 bp). RT-PCR was done on RNA, isolated from non-injected control (WT) and Dep1b-MO-injected embryos and the
resulting agarose gel is shown with the sizes of the bands indicated.
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bands of 333 bp and 313 bp, respectively, and the absence of the fully
spliced, mature RNA band of 287 bp (Fig. 2A). We conﬁrmed that the
slower migrating band represented unspliced RNA by sequencing
(data not shown). Translation of the unspliced RNAs would result in
premature stops and thus truncation of Dep1a, well upstream of the
catalytic site cysteine (Supplementary Fig. S1). We tried to detect
Dep1a protein in zebraﬁsh embryo lysates by immunoblotting using
anti-human Dep1 antibodies and using antibodies that we generated
using zebraﬁsh Dep1a catalytic domain as antigen. Unfortunately,
these antibodies did not allow us to detect endogenous Dep1 protein
in zebraﬁsh (data not shown).
Morphological examination of embryos injected with Dep1a-MO1
indicated that blood circulation was defective at 30 hpf. Notably, O-
dianisidine staining demonstrated that blood accumulated in the
posterior cardinal vein (PCV) (asterisk in Fig. 3B). Blood ﬂow was
reduced or absent through the dorsal aorta (DA) and blood
accumulated at the aortic bifurcation (arrow in Fig. 3B). MorphologicalFig. 3. Dep1a-MO induced blood circulation defects, but vasculogenesis appeared normal.
injected embryos at 48 hpf. The arrow indicates hemorrhages at the aortic bifurcation and th
zebraﬁsh embryos were injected with Dep1a-MO1 (D) or Dep1a-MO2 (E) at the 1-cell stage a
a control (C). Microangiography was done by injection of rhodamine-conjugated dextran
microscope. Non-injected control (F), Dep1a-MO1 injected (G) and Dep1a-MO2-injected
circulation is blocked (arrow).assessment of embryos injected with Dep1a-MO2 also indicated
reduced blood circulation through the axial vasculature (data not
shown). These observations contrast with the non-injected control,
where the blood is found mainly in the sinus venosus (SV) and in the
heart (Fig. 3A). It is noteworthy that injection of non-related
morpholinos, such as the Nacre-MO that induces pigmentation
defects, did not induce blood circulation defects (data not shown),
suggesting that the Dep1a-MO-induced defects were speciﬁc.
To investigate whether vasculogenesis was affected by Dep1a
knockdown, we micro-injected the Dep1a-MOs into ﬂi1a::egfp1
transgenic embryos that express GFP in all endothelial cells (Lawson
andWeinstein, 2002). Micro-injection of either Dep1a-MO1 or Dep1a-
MO2 did not induce apparent defects in vasculogenesis at 30 hpf (Figs.
3C–E). The overall vasculature appeared to be normal with clearly
distinguishable dorsal aorta, PCV and intersegmental vessels (Figs.
3C–E). Therefore, the observed accumulation of blood cells and defects
in blood circulation as a result of Dep1a knockdown were not the
result of gross defects in vasculogenesis.O-dianisidine staining of hemoglobin was done on wild type (A) and Dep1a-MO1 (B)
e asterisk blood accumulation around the posterior cardinal vein. Fli1a::egfp1 transgenic
nd the vasculature was visualized at 30 hpf. A non-injected ﬂi1a::gfp1 embryo served as
into the heart of embryos. Circulation of the dye was visualized using a ﬂuorescence
embryos (H) all at 48 hpf are depicted here. (J–K) Magniﬁcations of the area where
Fig. 4. Dep1a-MO induced reduction in dorsal aorta marker tbx20. (A) In situ
hybridization showing tbx20 expression in wild type zebraﬁsh embryo at 30 hpf and
in Dep1a-MO1 (B) or Dep1a-MO2 (C) injected embryos.
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performed by injection of ﬂuorescent rhodamine dextran. Inwild type
embryos, ﬂuorescence was detected throughout the entire aorta at
48 hpf (Figs. 3F, I). The microangiograms of Dep1a-MO1-injected
embryos showed defects at 48 hpf in the axial vasculature. Rhodamine
dextran staining was only found anterior to the aortic bifurcation and
no ﬂuorescence was detected in the posterior aorta (Figs. 3G, J).
Dep1a-MO2 similarly affected functionality of the vasculature, as
shown by the microangiogram of wild type embryos, injected with
Dep1a-MO2, in which the rhodamine dextran did not reach the
posterior part of the embryo (Figs. 3H, K). These experiments indicate
that Dep1a appears not to be required for vasculogenesis per se, but is
essential for functionality of blood vessels at 48 hpf.
To determine the nature of the defects that induced defective
blood circulation, we investigated expression of tbx20, a dorsal aorta
marker (Ahn et al., 2000). In situ hybridization using a tbx20 speciﬁc
probe conﬁrmed labeling of the dorsal aorta at 30 hpf (Fig. 4A). Tbx20
expression was reduced in both Dep1a-MO1- and Dep1a-MO2-
injected embryos (Figs. 4B, C). The reduction in tbx20 expression
was variable.We classiﬁed the defects in tbx20 expression in 3 classes:
class 1, normal wild type expression in the dorsal aorta; class 2 (mild),
patchy expression in some cells and class 3 (severe), tbx20 expressionFig. 5. Dep1a-MO-induced reduction in tbx20 expression was speciﬁc. (A) Classiﬁcation of
normal tbx20 expression (white), middle panel, mild effect, patchy tbx20 expression (orange)
Dep1a knockdown. The percentages of embryos in the three different classes is given in con
was co-injected with a CMV promoter-driven expression vector for Dep1a (12.5 ng), effect
experiments are indicated (n). Exact numbers are given in Supplementary Table S1. (C) Ex
transfected into COS cells. The cells were lysed and whole cell lysates were run on a 7.5% SDS-
MAb 9E10. An immunoblot is depicted developed with enhanced chemiluminescence and
indicated in kDa on the left.completely absent (Fig. 5A). We quantiﬁed the number of embryos in
each class, based on the classiﬁcation above and found that a
signiﬁcant proportion of the injected embryos displayed reduced
tbx20 expression (Fig. 5B, Supplementary Table S1).
To establish that the observed defects were speciﬁc, we performed
rescue experiments. Rescue experiments are usually done by co-
injection of MOs with synthetic RNA encoding the target protein. In
vitro synthesis of RNA encoding Dep1a did not yield sufﬁcient RNA for
the co-injections. Therefore, we co-injected a CMV promoter-driven
expression vector for zebraﬁsh Dep1a. This led to a signiﬁcant
reduction in the number of embryos with aberrant tbx20 expression
(Fig. 5B). The expression vector by itself did not affect tbx20
expression in injected embryos (Supplementary Table S1). The
expression vector for zebraﬁsh Dep1a contained a Myc epitope tag
immediately following the signal sequence, facilitating detection of
transgene expression. We transfected the Myc-tagged expression
vector for Dep1a into COS-1 cells and established its expression by
immunoblotting. As controls, we used Myc-tagged RPTPα and control
vector. As shown in Fig. 5C, Dep1awas detected as a band of ∼250 kDa,
using anti-Myc antibodies. Myc-tagged RPTPαwas detected as a broad
band of ∼180 kDa (Blanchetot et al., 2002). In embryos, expression of
Myc-tagged Dep1a was not detectable by immunohistochemistry,
which was presumably due to low expression levels of Dep1a.
Nevertheless, our data demonstrate that full length Dep1a was
produced from this expression vector and co-injection with Dep1a-
MO rescued the Dep1a knockdown phenotype, indicating that the
phenotype was speciﬁc.
Dep1a and Dep1b act synergistically in aorta formation
We hypothesized that Dep1a and Dep1b might have redundant
functions, because of their high similarity. To investigate this
hypothesis, we designed a Dep1b-MO directed at the exon–intron
boundary that corresponded to the Dep1a-MO1 target site (see
Supplementary Fig. S1). We established that micro-injection of this
Dep1b-MO blocked splicing (Fig. 2B). Co-injection of high amounts of
the Dep1a- and Dep1b-MOs (8 ng each) induced non-speciﬁc defects
in the embryos, including necrosis and oedemas (data not shown).
Therefore, we reduced the amount of eachMO to 4 ng. Micro-injection
of 4 ng Dep1a-MO or Dep1b-MO-induced defects in tbx20 expression,
albeit in a low percentage of the embryos (Figs. 6A–C, I,the observed defects after Dep1a-MO injection (8 ng/embryo): upper panel, no effect,
, lower panel, severe effect, no tbx20 expression (red). (B) Quantiﬁcation of the effects of
trol embryos (WT) and in Dep1a-MO1 (8 ng) injected embryos. Moreover, Dep1a-MO1
ively rescuing the defects. Total numbers of embryos from at least three independent
pression vectors for Myc epitope tagged Dep1a and – as a control – for RPTPα were
PAAGE gel. The material on the gel was blotted and the blots were probed with anti-Myc
the positions of marker proteins that were co-electrophoresed with the sample are
Fig. 6. Synergistic effects of Dep1a and Dep1b MOs. Dep1a- and Dep1b-MOs were (co-)
injected at the 1-cell stage (4 ng each) and the embryos were ﬁxed at 30 hpf. In situ
hybridizations were done using tbx20 speciﬁc probes (A–D), a cdh5 (ve-cadherin)-
speciﬁc probe (E,F) or myoD-speciﬁc probes (G,H). (I) Quantiﬁcation of defects in tbx20
expression, classiﬁed as outlined in Fig. 5. The total number of embryos that was
analyzed for each condition from three independent experiments is indicated here and
depicted in Supplementary Table S2.
Fig. 7. Dep1-MO induced reduction in arterial cell fate. Dep1a- and Dep1b-MOs were
co-injected and the embryos were ﬁxed at 30 hpf. Three arterial markers (notch5,
ephrinB2 and grl) and two venous markers (ephB4 and dab2) were used for in situ
hybridizations. The position of the dorsal aorta is indicated with an arrow.
126 F. Rodriguez et al. / Developmental Biology 324 (2008) 122–130Supplementary Table S2). However, co-injection of Dep1a- and
Dep1b-MOs strongly enhanced the percentage of embryos with
defective tbx20 expression, indicating that these MOs acted synergis-
tically (Figs. 6D, I; Supplementary Table S2). Co-injection of Dep1a-MO
or Dep1b-MO with the non-related Nacre-MO did not lead to an
increase in defects in tbx20 expression (Supplementary Table S2),
illustrating that this defect is speciﬁcally due to knockdown of the two
Dep1 proteins. Interestingly, cdh5 expression, a marker for vascular
endothelial cells, was not affected by injection of both Dep1a-MO and
Dep1b-MO (Figs. 6E, F). Moreover, the pattern of the somite marker
myoD was not affected either, indicating that somitogenesis was not
affected by Dep1 knockdown (Figs. 6G, H). Our results indicate that
Dep1a-MO and Dep1b-MO induced defects in the dorsal aorta on their
own. Moreover, combined, the Dep1a-MO and Dep1b-MO acted
synergistically, suggesting that the function of Dep1a and Dep1b is
partially overlapping.
Dep1a and Dep1b are required for arterial/venous fate decision
To further investigate the role of Dep1 in blood vessels, we
examined the arterial markers notch5, ephrinB2 and grl/hey2 and thevenous speciﬁc markers, ephB4 and dab2. Dep1a/Dep1b-MO injections
reduced expression of all three arterial markers (Fig. 7A). Notch5
expression was almost completely lost from the dorsal aorta where it
is normally expressed (Fig. 7A, cf. WT and Dep1a/Dep1b-MO).
EphrinB2 expression persists only in a patchy, non-continuous manner
in Dep1a/Dep1b morphants, whereas in non-injected control
embryos, ephrinB2 is expressed in a continuous line in the dorsal
aorta (Fig. 7A). Similarly, grl expression is almost completely lost from
the Dep1a/Dep1b-MO-injected embryos. This panel of arterial
markers suggests that arteries do not form properly.
The venous ephB4 and dab2 markers stain the PCV in the trunk of
wild type non-injected control embryos. EphB4 stainingwas expanded
in Dep1a/Dep1b morphants, compared to non-injected controls.
Moreover, the PCV appeared to be slightly enlarged (Fig. 7B). Similarly,
dab2 staining was expanded and the PCV was enhanced. It appeared
that ephB4 and dab2 were expressed where the dorsal aorta is
localized normally. Together, the venous and arterial markers
demonstrate that Dep1a/Dep1b-MOs induced a decrease in arterial
marker expression and a concomitant increase in venous marker
expression. These results suggest that Dep1a and Dep1b have a role in
the arterial cell fate decision of vascular endothelial cells.
The mechanism underlying the role of Dep1 in arterial/venous cell fate
decisions
Much work has been done on how the arterial/venous cell fate is
established. The model that is emerging is that sonic hedgehog (shh)
from the notochord induces vegf in somites, which in turn induces
notch5 and ﬂk1 in endothelial cells to induce arterial differentiation
(Lawson et al., 2002). Notch5 induces ephrinB2 and grl expression and
inhibits ﬂt4. Grl mutant zebraﬁsh display selectively perturbed artery
formation (Zhong et al., 2000) and the arterial/venous cell fate
decision is guided by grl (Zhong et al., 2001). Interestingly, the grl
Fig. 8. Rescue of Dep1 morphant phenotype by PI-3K inhibitor and expression of notchICD and grl. Effects of (co-)injection on arterial differentiation were assessed by in situ
hybridization, using a tbx20-speciﬁc probe. Rescues were done using the PI-3K inhibitor LY294002 (A), notchICD RNA (B) and grl RNA (C). The total numbers of embryos that were
used for each condition from three independent experiments are indicated (n) and are given in Supplementary Table S3.
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phenotype, in that grl mutants also show reduced arterial markers
(ephrinB2) and enhanced venous markers (ephB4) (Zhong et al., 2001).
We reproduced the grl phenotype using Grl-MOs and compared the
grl and Dep1a/Dep1b phenotypes side by side and found that the
Dep1 knockdown is a phenocopy of the grl knockdown (data not
shown). This may suggest that Dep1a/Dep1b acted through a similar
mechanism. In fact, we demonstrated that grl and notch5 expression
are strongly reduced in Dep1a/Dep1b knockdowns, indicating that
Dep1a/Dep1b are genetically upstream of notch and grl. Phosphatidy-
linositol-3 kinase (PI3K) inhibitors were identiﬁed in a screen for
suppressors of the grlmutant phenotype and PI3K inhibitors promote
arterial speciﬁcation (Hong et al., 2006).
We set out to address the mechanism underlying Dep1a/Dep1b
signaling by analysis of the potential to rescue the Dep1a/Dep1b-MO-
induced decrease in tbx20 expression by interference with known grl
signaling components. To this end, we used LY294002, a speciﬁc PI3K
inhibitor, which rescued the Dep1a/Dep1b induced phenotype (Fig.
8A; Supplementary Table S3), similar to LY-mediated rescue of the grl
phenotype (Hong et al., 2006). Co-injection of RNA encoding Notch
intracellular domain (notchICD) rescued the Dep1a/Dep1b-MO-
induced decrease in tbx20 expression (Fig. 8B; Supplementary Table
S3). Finally, the Dep1a/Dep1b knockdown was rescued by grl RNA
injection as well (Fig. 8C; Supplementary Table S3). Control gfp RNA
co-injections with Dep1a/Dep1b-MOs did not affect tbx20 expression
(data not shown). These results demonstrate that Dep1a/Dep1b
signaling counteracts PI3K signaling and is mediated by notch and
grl expression.
Discussion
Here, we provide evidence that the zebraﬁsh orthologs of Dep1,
Dep1a and Dep1b, act in arterial cell fate decision. We found that
inhibition of PI3K and expression of notchICD and grl rescued Dep1a/
Dep1b morphants, providing an underlying mechanism for the
function of Dep1.
Mouse mutants in which part of the catalytic domain of Dep1 was
replaced by GFP die at midgestation, before embryonic day 11.5.
Homozygous mutant embryos were indistinguishable from wild type
mice at embryonic day 8.5 in the gross appearance of the rostral–
caudal–dorsal aorta, anterior and posterior cardinal veins, vitelline
artery and vein and yolk sac capillary plexus. Therefore, Dep1appeared not to be required for early embryonic vasculogenesis.
However, by day 9, a collapse of the dorsal aorta was observed
accompanied by the presence of abundant endothelial cells. At
embryonic day 9.5, the dorsal aorta appeared as a disorganized string
of aligned endothelial cells and at embryonic day 10.5, its outline was
discontinuous (Takahashi et al., 2003). Surprisingly, deletion of exons
3, 4 and 5 of Dep1 did not affect embryonic development and Dep1−/−
micewere viable and fertile (Trapasso et al., 2006). There is an obvious
discrepancy in phenotypes between these two Dep1 mutant mouse
models, which may be due to the fact that the two mouse models are
inherently different. The knock out mice apparently do not express
Dep1 protein (Trapasso et al., 2006). Yet, the Dep1-GFP fusion protein
is expressed (Takahashi et al., 2003). Therefore, the Dep1-GFP fusion
protein may function by itself, albeit it lacks catalytic activity.
The zebraﬁsh knockdown phenotype was reminiscent of the
phenotype in mice in which the catalytic domain of Dep1 was
replaced by gfp sequences. The Dep1-MOs induced varying degrees of
reduction of the dorsal aorta marker, tbx20. Moreover, we have
observed that the dorsal aorta in sections of Dep1a/Dep1b-MO-in-
jected embryos apparently did not lumenize, which was accompanied
by an enlarged PCV (data not shown). Our data suggest that arterial
differentiation was reduced in Dep1 morphants, which was accom-
panied by ectopic expression of venous markers. This phenotype was
reminiscent of the grl mutant phenotype (Weinstein et al., 1995;
Zhong et al., 2001). We reproduced the grl phenotype by Grl-MO
injection and found that indeed, Dep1a/Dep1b morphants phenocop-
ied the Grl knockdown. Analysis of epigenetic interactions indicated
that co-injection of Dep1-MOs with Grl-MO was additive, as assessed
by tbx20 expression (data not shown). Importantly, Dep1-MOs
abolished grl expression in the dorsal aorta, suggesting that Dep1
acts upstream in a signaling pathway regulating grl expression. Grl
RNA injection was sufﬁcient to rescue Dep1a/Dep1b knockdown,
conﬁrming that Dep1 and Grl interact genetically. Moreover, expres-
sion of notch5 was reduced in Dep1a/Dep1b morphants and RNA
encoding NotchICD, a known factor upstream of grl, rescued Dep1a/
Dep1b-MO injection. Finally, we demonstrated that the PI3K inhibitor
LY294002 that was reported to rescue the grl phenotype, also rescued
the Dep1a/Dep1b knockdown phenotype. Our data ﬁrmly place Dep1
upstream in a cascade, involving PI3K, notch and grl.
The soluble factor VEGF is an important regulator of arterial/
venous cell fate decisions (Lawson et al., 2002). Dep1 may act directly
on VEGFR2 signaling, as it has been demonstrated in tissue culture
Fig. 9.Model for the role of Dep1 in arterial speciﬁcation. Dep1 may act at or upstream
of PI3K, inhibiting Akt/PKB activation, thus relieving inhibition of the RAF–MEK–ERK
pathway. This pathway regulates expression of Notch and Grl, positive regulators of the
arterial marker, EphrinB2, and negative regulators of venous EphB4. Absence of Dep1
was rescued by PI3K inhibitor (LY294002) and by expression of Notch and Grl.
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phosphorylation (Lampugnani et al., 2003). Whether Dep1 acts
through VEGFR2 signaling in arterial differentiation during zebraﬁsh
development remains to be determined.
In C. elegans, the Dep1 ortholog is involved in cell fate decisions
in vulval development. Dep1 inhibits the primary cell fate speciﬁca-
tion in the future secondary cells by induction of the transcription of
a set of inhibitors of the EGFR/RAS/MAPK signaling pathway (Berset
et al., 2005). Our data suggest that Dep1 has a role in cell fate
decisions in zebraﬁsh as well, in that Dep1 is required for arterial
speciﬁcation. Interestingly, Notch signaling is repressed in the
primary cells in C. elegans and acts in parallel to Dep1 in secondary
cells. Similarly, Notch is expressed in the dorsal aorta in zebraﬁsh,
but not in venous cells, suggesting it has a similar decisive role in cell
differentiation as in C. elegans. However, in zebraﬁsh, Dep1-MO
injections result in loss of notch5 expression in future dorsal aorta
cells and notchICD expression rescued Dep1 morphants, indicating
that Dep1 acts upstream of Notch in arterial cell differentiation, not
in parallel to Notch as in C. elegans. Nevertheless, there are parallels
between Dep1 signaling in C. elegans and in zebraﬁsh, in that Dep1
has a decisive role in cell fate determination.
Taken together, our data suggest a model that builds on previous
models for the role of Dep1 in cell speciﬁcation (Berset et al., 2005;
Hong et al., 2006) in which Dep1 acts at the level of PI3K or upstream
(Fig. 9). Inhibition of PI3K by Dep1 relieves inhibition of the RAF–
MEK–ERK pathway which controls Notch and Grl expression and thus
arterial speciﬁcation. In the absence of Dep1, arterial speciﬁcation is
reduced, which is rescued by the PI3K inhibitor LY294002 and by
expression of Notch and Grl, restoring the pathway (Fig. 9).
Our results indicate that zebraﬁsh Dep1 acted in arterial cell fate
determination and we provide evidence that Grl and Notch were
involved. Future work should focus on whether Dep1 acts on the
VEGFR2–RAF–MEK–ERK signaling pathway.
Materials and methods
Zebraﬁsh lines and maintenance
Zebraﬁsh were maintained and staged according to standard
protocols (Westerﬁeld,1995). The zebraﬁsh lines we used are the ABTL
strains and the transgenic line ﬂi1a::egfpy1 (Lawson and Weinstein,
2002).Cloning of zebraﬁsh Dep1a and Dep1b sequences
To identify the zebraﬁsh Dep1 orthologue, a BLAST search of human
Dep1 protein (SWISSPROT number: Q12913) against the zebraﬁsh
translated database (tblastn) Zv6 Ensembl genome assembly was
performed (www.ensembl.org). Two genes encoding Dep1 protein,
Dep1a, in LG7 at position 51.7 Mb (ENSDARG00000011567) and Dep1b,
LG25at position 22.2Mb (ENSDARG00000033042),were identiﬁed. Full
length Dep1a was ampliﬁed from 3 dpf zebraﬁsh cDNA generated by
oligod(T) using standard PCR conditions. Five overlappingPCRproducts,
covering the entire predicted cDNA of Dep1a were ampliﬁed and
subcloned in pBluescript SK+. The sequence was veriﬁed and all ﬁve
clones were assembled together in pCS2+ plasmid. The Dep1a coding
sequence without its signal sequence was fused in-frame to the signal
sequence of RPTPα and in-frame Myc-tag (Blanchetot et al., 2002),
allowing expression of Myc-tagged transmembrane proteins. A frag-
ment of Dep1b (660 bp) encompassing the PTP domain was ampliﬁed
from a 2 dpf zebraﬁsh total RNA by RT-PCR. The fragment was then
subcloned in pBluescript SK+ and veriﬁed by sequencing.
Phylogenetic reconstruction
As input for theMEG3.1 program (Molecular Evolutionary Genetics
Analysis, version 3.1), we used protein sequences of the PTP domain of
human Dep1 (Swissprot Q12913), mouse Dep1 (Swissprot Q64455),
zfDep1a and zfDep1b (ENSDARG00000011567 and ENSDAR-
G00000033042), human PTPβ (Swissprot P23476), mouse PTPβ
(NM_029928), zfPTPβ (ENSDARG00000006391), human SAP1
(Swissprot Q15426), mouse SAP1 (NP_997153) and zfPTPSAP1a
(ENSDARG00000063620). The protein sequences from zebraﬁsh
PTPβ and zebraﬁsh SAP1 were found by blasting their human
homologues against the zebraﬁsh Zv6 Ensembl genome assembly.
The phylogenetic tree was built with Neighbor-joining algorithmwith
a pair-wise deletion option and using Dayhoff Matrix Model. Support
for each node was determined by a bootstrap test.
In situ hybridization
Whole-mount in situ hybridizations were performed essentially as
described (Thisse et al., 1993) except for the Dep1a and Dep1b in situ
hybridizations in which the staining was developed in staining buffer
containing polyvinylalcohol (PVA) (100 mM tris–HCL pH=9.5, 100 mM
NaCl, 0.1% Tween, 50 mMMgCl2, 10% PVA, 0.17 mg/ml NBT, 0.17 mg/ml
BCIP). The probeswe used have been described before: tbx20 (Ahn et al.,
2000), cdh5/ve-cad (Larson et al., 2004), myoD (Weinberg et al., 1996),
notch3/5 (Gering and Patient, 2005), ephrinB2a and ephB4 (Cooke et al.,
2001), dab2 (Song et al., 2004), grl (Zhong et al., 2000). We used
fragments of dep1a and dep1b, encompassing the catalytic PTP domains
as probes for in situ hybridization.
Morpholinos, RNA and injections
Antisense MOs were designed to target exon–intron splice sites of
genomic Dep1a and Dep1b and ordered from GeneTools (Philomath,
OR, USA):
Dep1a-MO1 5′-TGAGGTTCTTACATGGCAGCACATT
Dep1a-MO2 5′-TTTCACTTCCTACCGGCATGTAGTT
Dep1b-MO1 5′-GAAGATACTCACAAGGTAAAACATT.
Morpholinos were diluted in 1×Danieau buffer (58 mM NaCl,
0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5 mM Hepes pH 7.6)
and 1 nl was injected into embryos at 1–2 cell stage in concentrations
ranging from 1–15 ng/nl. mMESSAGEmMACHINE kit (Ambion, Austin,
TX, USA) was used to synthesize 5′ capped sense RNAs for full length
grl (RZPD, Berlin, Germany) and notchICD (gift of Dana Zivkovic).
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or synthetic RNA (0.5–50 pg/nl) were (co-)injected into 1 cell stage
embryos and phenotypes were assessed at the indicated stages.
RT-PCR
Total RNA from 2 dpf-old wild type and MO-injected embryos
(Dep1aMO1: 4 ng/nl, Dep1aMO2: 12 ng/nl, Dep1bMO: 8 ng/nl) was
isolated using guanidine isothiocyanate (GIT) method. Following
DNAse treatment (Ambion, Austin, TX, USA) of the total RNA, reverse
transcription was done using M-MLV-RT (Isogen, IJsselstein, the
Netherlands) and subsequently, PCR was done using standard
protocols, using appropriate oligonucleotides.
O-dianisidine staining
O-dianisidine (Sigma-Aldrich, St. Louis, MO, USA) was used to
detect hemoglobin exactly as described previously (Kawahara and
Dawid, 2001).
Microangiography
Rhodamine-conjugated dextran (Tetramethylrhodamine,
2.000.000 MW, Invitrogen, Carlsbad, CA, USA) was injected in the
heart of embryos slightly anaesthetized with tricaine (MS222) and
mounted in 0.8% low melting agarose (Isogai et al., 2001). Fluorescent
dextran was visualized using a Leica ﬂuorescence microscope.
PI-3 kinase inhibitor LY 294002
Embryos were grown in embryo medium and at 4 hpf various
concentrations of LY 294002 inhibitor (Calbiochem, San Diego, CA, USA)
ranging from 2.5 to 15 μMwere added. Control embryoswere incubated
with equal amounts of solvent (DMSO). Embryos were scored at 30 hpf
by ﬁxing and in situ hybridization using a tbx20 speciﬁc probe.
Transfections
COS-1 cells were grown in Dulbecco's modiﬁed Eagle's medium/
F12 supplemented with 7.5% Fetal Calf Serum. Dep-1 constructs were
transfected by calcium phosphate precipitation as described pre-
viously. Cells were harvested by lysis in 50 mMHEPES pH 7.5, 150 mM
NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 1 mM
aprotinin, 1 mM leupeptin, and 1 mM ortho-vanadate. Cell lysates
were cleared and an aliquot was boiled in equal volume 2× Laemmli
Sample Buffer and run on a 7.5% SDS-PAGE gel. Proteins were
subsequently transferred by semi-dry blotting to a PVDF membrane.
Immunoblotting was done using standard protocols. The blots were
probed with anti-Myc monoclonal antibody 9E10 and with afﬁnity
puriﬁed anti-zebraﬁsh Dep1a antibody that we raised against a GST-
fusion protein encoding the catalytic domain of Dep1a. The immuno-
blots were visualized by Enhanced Chemiluminescence (ECL).
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